期刊
JOURNAL OF CLINICAL MICROBIOLOGY
卷 59, 期 8, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.00319-21
关键词
COVID-19; ELISA; SARS-CoV-2; flow cytometry bead-based surrogate test; lateral flow assay; plaque-reduction neutralization test
类别
资金
- Federal Ministry for Education and Science (BMBF) [03COV26A]
- Free State of Bavaria
- COVID research funds
A study compared the performance of seven serological assays for COVID-19, with only one commercial immunoassay showing both sensitivity and specificity greater than 98%. Neutralizing antibodies were detected in a high percentage of COVID-19 survivors.
For the control of immunity in COVID-19 survivors and vaccinated subjects, there is an urgent need for reliable and rapid serological assays. Based on samples from 63 COVID-19 survivors up to 7 months after symptom onset, and on 50 serum samples taken before the beginning of the pandemic, we compared the performances of three commercial immunoassays for the detection of SARS-CoV-2 IgA and IgG antibodies (Euroimmun SARS-COV-2 IgA/IgG, Mikrogen recomWell SARS-CoV-2 IgA/IgG, and Serion ELISA agile SARS-CoV-2 IgA/IgG) and three rapid lateral flow (immunochromatographic) tests (Abbott PanBio COVID-19 IgG/IgM, Nadal COVID-19 IgG/IgM, and Cleartest Corona 2019-nCOV IgG/IgM) with a 50% plaque-reduction neutralization test (PRNT50) representing the gold standard. Fifty-seven out of 63 PCR-confirmed COVID-19 patients (90%) showed neutralizing antibodies. The sensitivity of the seven assays ranged from 7.0% to 98.3%, and the specificity ranged from 86.0% to 100.0%. Only one commercial immunoassay showed a sensitivity and specificity of greater than 98%.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据